Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
8.05
-0.01 (-0.12%)
At close: Aug 28, 2025, 4:00 PM
8.05
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:10 PM EDT
Nasus Pharma Statistics
Total Valuation
Nasus Pharma has a market cap or net worth of $72.93 million. The enterprise value is $74.27 million.
Market Cap | 72.93M |
Enterprise Value | 74.27M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Nasus Pharma has 9.06 million shares outstanding. The number of shares has decreased by -0.43% in one year.
Current Share Class | 9.06M |
Shares Outstanding | 9.06M |
Shares Change (YoY) | -0.43% |
Shares Change (QoQ) | +4.01% |
Owned by Insiders (%) | 43.04% |
Owned by Institutions (%) | n/a |
Float | 3.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
Current Ratio | 0.12 |
Quick Ratio | 0.10 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -37.17 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -116.06% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 33.56% |
Revenue Per Employee | n/a |
Profits Per Employee | -$766,000 |
Employee Count | 2 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | n/a |
Average Volume (20 Days) | 63,504 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.08M |
Pretax Income | -1.53M |
Net Income | -1.53M |
EBITDA | n/a |
EBIT | -1.08M |
Earnings Per Share (EPS) | -$0.22 |
Balance Sheet
The company has $284,000 in cash and $1.80 million in debt, giving a net cash position of -$1.52 million or -$0.17 per share.
Cash & Cash Equivalents | 284,000 |
Total Debt | 1.80M |
Net Cash | -1.52M |
Net Cash Per Share | -$0.17 |
Equity (Book Value) | -3.21M |
Book Value Per Share | -0.44 |
Working Capital | -3.47M |
Cash Flow
Operating Cash Flow | -665,000 |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nasus Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.43% |
Shareholder Yield | 0.43% |
Earnings Yield | -2.11% |
FCF Yield | n/a |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |